Metsera (NASDAQ:MTSR) Trading Down 5.2% - Time to Sell?

Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s share price fell 5.2% on Friday . The stock traded as low as $32.44 and last traded at $32.79. 210,943 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 902,864 shares. The stock had previously closed at $34.58.

Analysts Set New Price Targets

Several brokerages recently weighed in on MTSR. Guggenheim boosted their price objective on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday. Cantor Fitzgerald initiated coverage on Metsera in a report on Tuesday, February 25th. They issued an "overweight" rating for the company. Evercore ISI initiated coverage on Metsera in a report on Tuesday, February 25th. They set an "outperform" rating for the company. Finally, Bank of America initiated coverage on Metsera in a report on Tuesday, February 25th. They set a "buy" rating and a $38.00 target price for the company.

Metsera Stock Down 15.0%

The company's fifty day moving average is $24.39.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($1.03) EPS for the quarter.

Hedge Funds Weigh In On Metsera

Hedge funds and other institutional investors have recently made changes to their positions in the business. Strs Ohio acquired a new position in shares of Metsera during the first quarter worth approximately $76,000. New York State Common Retirement Fund acquired a new position in shares of Metsera during the first quarter worth approximately $131,000. Corebridge Financial Inc. acquired a new position in shares of Metsera during the first quarter worth approximately $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Metsera during the first quarter worth approximately $248,000. Finally, MetLife Investment Management LLC acquired a new position in shares of Metsera during the first quarter worth approximately $254,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.